Introduction
============

Aging of the population, worsening risk factor profile, and improved care of acute cardiovascular disease (CVD) have all led to an increase in the prevalence of heart failure (HF).^[@b1]^ Heart failure is associated with an unacceptably high morbidity and mortality^[@b2]^ and imposes a significant economic burden, underscoring the need to identify high‐risk individuals in order to tailor preventive and therapeutic measures. Resting heart rate (RHR) is independently associated with prognosis among patients with prevalent HF and RHR lowering has been demonstrated to benefit patients with HF and reduced ejection fraction.^[@b3]--[@b5]^ Whereas, some studies have suggested a positive association between baseline RHR and incident HF risk,^[@b6]--[@b7]^ others have only shown a sex‐differentiated association,^[@b8]^ with uncertainties remaining about the shape of this association due to the small size of the prior investigations. Most studies have included individuals from select population^[@b9]^ or patients with pre‐existing disease^[@b3]^ or using drugs that modify heart rate.^[@b10]^ It is important to assess the association of RHR with risk of HF prospectively in order to also avoid the potential bias of reverse causality. In this study, we sought to assess the association between RHR and incident HF in 3 population‐based cohort studies by performing an individual participant meta‐analysis of these cohorts. To contextualize our findings, we also performed a systematic review and meta‐analysis of the published prospective evidence on the association of RHR and risk of incident HF.

Methods
=======

Study Populations
-----------------

The 3 cohort studies that were included were the Heath Aging and Body Composition (Health ABC) study, the Cardiovascular Health Study (CHS), and the Kuopio Ischemic Heart Disease (KIHD) study. The Health ABC Study is a community‐based cohort of 3075 individuals aged 70 to 79 years at inception.^[@b11]--[@b12]^ Participants were identified from a random sample of white Medicare beneficiaries and all age‐eligible black residents in designated zip codes surrounding Pittsburgh, PA and Memphis, TN. To be eligible, participants had to report no difficulty walking one‐quarter of a mile or climbing 10 stairs without resting. Exclusion criteria included difficulties with activities of daily living, obvious cognitive impairment, or intention of moving within 3 years. Baseline data were collected in 1997--1998.^[@b11]--[@b12]^ The design and rationale of CHS has been previously published.^[@b13]^ Briefly, non‐institutionalized individuals 65 to 100 years old were recruited from Medicare eligibility lists and examined at 4 field centres in Forsyth County, NC; Sacramento County, CA; Allegheny County, PA; and Washington County, MD). An original cohort of 5201 participants was recruited in 1989--1990 and a second cohort of 687 black participants was recruited in 1992--1993 (total, 5888 participants; 2495 men, 3393 women). KIHD study is a population‐based study, representative of men living in the city of Kuopio and its surrounding rural communities in Eastern Finland.^[@b18]^ The men were 42 to 61 years of age during baseline examinations performed between March 20, 1984 and December 5, 1989. Of 3235 potentially randomly selected eligible men, 2682 (83%) volunteered to participate in this study, 186 did not respond to the invitation, and 367 declined to give informed consent.^[@b18]^ Each cohort study was approved by its Institutional Research Ethics Committee, and each participant gave written informed consent.^[@b11]--[@b12],[@b18]^

For the current analysis, we created an individual‐level pooled dataset from CHS, Health ABC study, and KIHD study for participants without prevalent HF who did not have any major electrocardiographic abnormalities at baseline (ventricular conduction defect, major Q‐wave abnormality, isolated ST‐T wave abnormalities, atrial fibrillation, or atrio‐ventricular blocks). Prevalent HF was adjudicated on the basis of self‐report, medications, and review of medical records. From the 5888 CHS participants we excluded those with prevalent HF (n=275) and individuals with major ECG abnormalities (N=1550). From the 3075 Health ABC participants, we excluded those with prevalent HF (n=95) or inadequate data to adjudicate HF (n=45) and those with major ECG abnormalities (n=1102) at baseline. From KIHD we excluded those with prevalent HF (n=194) and those with major ECG abnormalities (n=164). The final cohort for this analysis comprised 7073 participants with non‐missing data at baseline on several HF risk factors including age, sex, body mass index, diabetes status, history of hypertension, left ventricular hypertrophy, and serum creatinine levels.

Study Outcomes
--------------

We used 10 plus‐year adjudicated outcomes from all 3 prospective studies for this analysis. In the Health ABC and CHS studies, all participants were asked to report any hospitalizations every 6 months and were asked direct questions about interim events. Medical records for overnight hospitalizations were reviewed at each site. All first admissions with an overnight stay that was confirmed as related to HF were classified as incident HF. Heart failure diagnosis was adjudicated based on symptoms, signs, chest radiograph results, and echocardiographic findings.^[@b13]^ The criteria required at least HF diagnosis from a physician and treatment for HF.^[@b12]^ In addition, data on left ventricular ejection fraction during the index HF hospitalization was available in a subset of HF cases. All deaths were reviewed by each study\'s diagnosis and disease ascertainment committee and underlying causes of death were determined by central adjudication. In the KIHD study, participants are under continuous surveillance for the development of new CVD events, including new incident HF cases^18^. The sources of information on HF were based on hospital records and medico‐legal reports. The diagnostic classification of HF cases were coded according to *the International Classification of Disease, Tenth Revision* (*ICD‐10*) *codes* (I00 to I99) and (I50.0 to I50.9, I11, I42.0 to I42.9). The diagnosis of HF was based on a previous history of heart disease, physical examination by a doctor, laboratory investigations including the determination of natriuretic peptides, echocardiography, as well as electrocardiographic findings. Data on incident acute coronary events and deaths were obtained by computer linkage to the national hospital discharge and death certificate registers.^[@b9]^

Study Definitions
-----------------

Resting heart rate (bpm) was automatically measured from a 12‐lead electrocardiogram recorded in the morning as part of the baseline enrollment visit, along with fasting venous blood sample collection. Race was self‐reported. Hypertension was defined as self‐reported history of physician diagnosis accompanied by use of antihypertensive medications. Diabetes mellitus was considered present if the participant reported a history of diabetes mellitus or use of anti‐hyperglycemic medication. Smoking was defined as current, past (≥100 lifetime cigarettes), or never. Left ventricular hypertrophy was diagnosed based on the following criteria; R amplitude \>26 mm in either V5 or V6, or \>20 mm in any of leads I, II, III, aVF, or \>12 mm in lead aVL or R in V5 or V6 plus S amplitude in V1 \>35 mm. Prevalent HF was based on hospital records and medico‐legal reports. Prevalent coronary artery disease (CAD) was defined as: (1) history of surgical or percutaneous revascularization; or (2) electrocardiographic evidence of myocardial infarction; or (3) self‐reported history of myocardial infarction or angina accompanied by use of anti‐anginal medications. Incident CAD was defined as hospitalization for myocardial infarction or angina pectoris, or elective revascularization. Prevalent vascular disease was defined as prevalent: (1) CAD; (2) cerebrovascular disease (history of stroke, transient ischemic attack, or carotid endarterectomy); or (3) PVD (history of intermittent claudication or vascular bypass or angioplasty).^[@b14]--[@b15]^ Incident vascular disease was defined as incident (1) CAD; (2) cerebro‐vascular disease (stroke, transient ischemic attack, or symptomatic carotid artery disease); (3) PVD; or (4) death due to cardiovascular causes.

Statistical Analysis
--------------------

The principal analyses were pre‐specified to exclude participants with a history of HF and major ECG abnormalities at baseline. Cross‐sectional associations of RHR with various risk factors were assessed using linear regression models adjusted for cohort, age, and sex. The primary outcome was incident HF, defined as first‐ever nonfatal hospital admission for HF. Participants contributed only follow‐up time to recorded first HF outcome. Time‐to‐event analyses were conducted using Cox proportional hazard models, stratified by cohort and sex. The proportional hazards assumptions were tested as previously described and satisfied.^[@b16]^ To characterize shapes of associations, multivariate fractional polynomial models were fitted to data. In secondary analyses of the individual studies, the hazards were further adjusted for several potential confounders, including glucose, log~e~ triglycerides, cholesterol, HDL‐c, albumin, log~e~ C‐reactive protein (CRP). Subgroup analyses were conducted using interaction tests to assess statistical evidence of any differences in hazards across levels of pre‐specified individual level characteristics, including age at survey, smoking, history of diabetes mellitus, history of hypertension, history of cardiovascular disease, left ventricular hypertrophy, history of anti‐hypertensive medication use, body mass index, and systolic blood pressure.

Meta‐Analysis
-------------

A systematic review was conducted using a predefined protocol and in accordance with the PRISMA and MOOSE guidelines^[@b17]--[@b18]^ (Appendices S1 and S2). Prospective (cohort or nested case‐control) studies of the association between resting heart rate and incident heart failure that were published up to March 2014 were sought using computer‐based databases (MEDLINE, EMBASE, and Science Citation Index). We crossed the term "heart rate" (and similar) with HF, left ventricular dysfunction (and similar terms) without any language restrictions. Reference lists of the retrieved articles were searched for additional articles. Studies were eligible for inclusion if they had at least 1 year of follow‐up and had recruited participants from approximately general populations (ie, did not select participants on the basis of pre‐existing disease at baseline). Hazard ratios and risk ratios were assumed to approximate the same underlying measure of relative risk (RR),^[@b19]^ henceforth referred to as risk ratios (RRs). Reported study‐specific RRs were converted to a consistent comparison as described previously.^[@b20]^ Note the log risk ratio for a 1 SD change is equivalent to the log risk ratio for a comparison of extreme quarters divided by 2.54 assuming a normal distribution or that a transformation of the explanatory variable for which the risk ratio is based was normally distributed. Risk estimates were transformed and pooled to involve comparisons between the top fourth and bottom fourth of the baseline levels of RHR. Study‐specific RRs were combined using a random‐effects meta‐analysis (subsidiary analyses used a fixed effect meta‐analysis). Standard errors of the log risk estimates were calculated using published confidence limits and were standardized in the same way. Consistency of findings among studies was assessed by Cochran\'s Q statistic (χ^2^ test) and the I^2^ statistic.^[@b21]--[@b22]^ Several study‐level characteristics were pre‐specified as characteristics for assessment of heterogeneity, which was conducted using stratified analyses and random effects meta‐regression.^[@b22]^ All statistical analyses were conducted using Stata version 13 (Stata Corp, College Station, TX).

Results
=======

Study Population
----------------

[Table 1](#tbl01){ref-type="table"} summarizes baseline characteristics of the 4095 participants in the CHS, 1269 participants in Health ABC Study and 1709 participants in the KIHD Study. The mean age of participants was 67 (9.9) years and 3815 (53.9%) were males. Mean RHR was 64.6 (11.1) bpm. During 92 702 person‐years at risk, there were 1189 incident HF events. Of these, 693 (58.3%) has had ejection fraction determined and documented at the time of HF diagnosis. The median ejection fraction was 50%. Overall 294 (42.4%) had preserved ejection fraction (≥45%) and 399 (57.6%) had reduced ejection fraction (\<45%).

###### 

Baseline Characteristics of the Study Participants

                                                               Overall (N=7073)      Cardiovascular Health Study (N=4095)   Health ABC Study (N=1269)   Kuopio Ischemic Heart Disease (N=1709)
  ------------------------------------------------------------ --------------------- -------------------------------------- --------------------------- ----------------------------------------
  Heart rate, bpm                                              64.6 (11.1)           65.1 (11.5)                            66.0 (10.0                  62.6 (10.6)
  Age at baseline, y                                           67.8 (9.9)            72.4 (5.4)                             73.4 (2.9)                  52.7 (4.9)
  Males, %                                                     3815 (53.9%)          1591 (38.5%)                           515 (40.7%)                 1709 (100.1%)
  Current cigarette smoker                                     1029 (14.3%)          492 (12.1%)                            537 (41.8%)                 560 (33%)
  Body mass index, kg/m^2^                                     26.9 (4.5)            26.6 (4.7)                             27.7 (4.9)                  26.9 (3.5)
  History of hypertension                                      3439 (48.4%)          2278 (56.1%)                           661 (51.7%)                 500 (29.7%)
  History of diabetes                                          836 (12.1%)           562 (13.2%)                            194 (15.4%)                 80 (4.4%)
  History of cardiovascular disease                            1491 (20.9%)          707 (17.6%)                            238 (18.7%)                 546 (31.9%)
  Left ventricular hypertrophy                                 416 (5.5%)            248 (6.6%)                             149 (12.1%)                 19 (1.1%)
  Use of anti‐hypertensive agents                              2417 (34.2%)          1739 (42.5%)                           668 (52.6)                  10 (0.6%)
  Total cholesterol, mg/dL                                     215.8 (40.4)          213.0 (38.6)                           207.3 (38.9)                228.9 (42.5)
  HDL cholesterol, mg/dL                                       54.2 (15.4)           55.4 (16.0)                            55.9 (17.1)                 50.0 (11.5)
  Triglycerides, mg/dL[\*](#tf1-1){ref-type="table-fn"}        113.0 (86.0, 156.0)   119.0 (92.0, 163.0)                    119.0 (91.0, 162.5)         94.7 (69.0, 131.9)
  Creatinine, mg/dL                                            1.0 (0.3)             1.0 (0.3)                              1.0 (0.3)                   1.0 (0.3)
  Fasting glucose, mg/dL[\*](#tf1-1){ref-type="table-fn"}      97.0 (90.0, 107.0)    100.0 (94.0, 110.0)                    94.0 (87.0, 106.0)          96.0 (22.0)
  Albumin, g/dL                                                4.0 (0.3)             4.0 (0.3)                              4.0 (0.3)                   N/A
  C‐reactive protein, mg/dL[\*](#tf1-1){ref-type="table-fn"}   2.2 (1.1, 4.0)        2.4 (1.2, 4.3)                         1.7 (1.0, 3.2)              N/A

ABC indicates Aging and Body Composition; HDL, high‐density lipoprotein.

Median (IQR) is presented for skewed variables.

Correlates of Resting Heart Rate
--------------------------------

Heart rate was found to be significantly lower (2.6 bpm) in males than in females. After adjusting for age and sex, there remained modestly weak positive correlation between RHR and body mass index (*r*=0.10), fasting glucose (*r*=0.18) and log~e~ C‐reactive protein (*r*=0.20), and weaker association with log~e~ triglycerides (*r*=0.08) and total cholesterol (*r*=0.05). Negative correlations were observed with serum albumin (*r*=−0.05), and creatinine levels (*r*=−0.05, [Table 2](#tbl02){ref-type="table"}). Resting heart rate was 4.8 bpm higher in individuals with diabetes mellitus, and 1 bpm higher in those with hypertension (*P*\<0.001). Individuals receiving beta‐blockers, on average had 5 bpm lower RHR than those not receiving beta‐blockers.

###### 

Correlation Between Resting Heart Rate and Baseline Characteristics

  Characteristics                     Resting Heart Rate
  ----------------------------------- -------------------------------------------------------------------------------------------------------
  Continuous variable                 Partial correlation (95% CI) or change relative to ref category[\*](#tf2-1){ref-type="table-fn"}
  Age, y                              0.01 (−0.05 to 0.06)
  Body mass index, kg/m^2^            0.10 (0.03 to 0.15)
  Systolic blood pressure, mm Hg      0.11 (−0.03 to 0.24)
  Diastolic blood pressure, mm Hg     0.16 (0.05 to 0.27)
  Triglycerides, mg/dL                0.08 (0.06 to 0.11)
  Serum total cholesterol, mg/dL      0.05 (0.02 to 0.07)
  Serum HDL‐cholesterol, mg/dL        0.00 (−0.06 to 0.06)
  Fasting blood glucose, mg/dL        0.18 (0.14 to 0.21)
  Creatinine, mg/dL                   −0.05 (−0.07 to −0.02)
  Albumin, g/dL                       −0.05 (−0.07 to −0.02)
  C‐reactive protein, mg/dL           0.20 (0.17 to 0.22)
  Categorical variable                Change relative to ref. category[\*](#tf2-1){ref-type="table-fn"}^,^[\*](#tf2-2){ref-type="table-fn"}
  Males                               −2.68 (−3.37 to −1.99)
  Current smoking                     1.16 (−0.98 to 3.30)
  History of diabetes                 4.75 (3.86 to 5.64)
  Hypertension                        1.00 (0.45 to 1.55)
  Left ventricular hypertrophy        0.82 (−1.05 to 2.69)
  History of coronary heart disease   −1.44 (−2.34 to −0.54)
  History of cardiovascular disease   −0.64 (−1.30 to 0.03)
  Regular use of medication           
  Antihypertensive drugs              0.14 (−0.64 to 0.91)
  β‐blockers                          −5.04 (−6.24 to −3.84)

HDL indicates high‐density lipoprotein.

Age adjusted partial correlation coefficient (95% confidence interval, CI) or change relative to the reference category for categorical variables.

Reference is the category without the characteristic: eg, non‐smokers for smoking.

Resting Heart Rate and Risk for Heart Failure
---------------------------------------------

In analyses adjusted for conventional risk factors (age, sex, smoking, body mass index, diabetes, history of hypertension, left ventricular hypertrophy, and systolic blood pressure), there was a nonlinear association between RHR and incident HF ([Figure 1](#fig01){ref-type="fig"}). The age and sex‐adjusted hazard ratio (HR) comparing the top (\>72 bpm) versus the bottom (\<57 bpm) fourth of RHR was 1.48 (1.26 to 1.74), which attenuated to 1.30 (1.10 to 1.53) with further adjustment for other conventional risk factors ([Table 3](#tbl03){ref-type="table"}). Beyond a RHR of 60 bpm, a linear association was observed with an overall hazard ratio of 1.13 (1.07 to 1.18, *P*\<0.001 per 10 bpm). Hazards did not vary significantly by levels of several conventional cardiovascular risk factors ([Figure 2](#fig02){ref-type="fig"}), and were similar in analyses that adjusted for incident Coronary Heart disease (CHD) events ([Table 3](#tbl03){ref-type="table"}), excluding HF events recorded in the first 2 years of follow‐up, excluding individuals with a history of CVD at baseline, or those individuals who were using beta‐blockers ([Table 3](#tbl03){ref-type="table"}). The association of RHR with incident HF was similar in those with preserved (HR: 1.10, 95% CI 0.96 to 1.26, *P*=0.182) versus reduced (HR: 1.33, 95% CI 1.13 to 1.56, *P*=0.001) ejection fraction per 10 bpm increase in resting heart rate, *P* value of heterogeneity=0.121). Among 4095 participants (857 HF cases) in the CHS, the hazard ratio was 1.36 (1.12 to 1.64); in 1269 participants (177 HF cases) in the Health ABC study, the hazard ratio was 1.23 (0.82 to 1.84); and in 1709 participants in the KIHD study (171 HF cases), the hazard ratio was 1.32 (0.83 to 2.08) comparing top versus bottom fourth of resting heart rate levels.

###### 

Association Between Heart Rate and Heart Failure

                                                                                                                     Resting Heart Rate (bpm)                                               
  ------------------------------------------------------------------------------------------------------------------ -------------------------- --------------------- --------------------- ---------------------
  3 studies, 7073 participants 1189 cases                                                                                                                                                   
  Age, sex                                                                                                           1.00 (Ref)                 0.87 (0.73 to 1.03)   1.12 (0.96 to 1.32)   1.48 (1.26 to 1.74)
  \+ Body mass index, history of diabetes, hypertension, smoking status, creatinine & left ventricular hypertrophy   1.00 (Ref)                 0.83 (0.70 to 0.99)   1.12 (0.96 to 1.32)   1.30 (1.10 to 1.53)
  3 studies, 7049 participants 1186 cases                                                                                                                                                   
  Basic model[\*](#tf3-1){ref-type="table-fn"}                                                                       1.00 (Ref)                 0.83 (0.70 to 0.99)   1.05 (0.89 to 1.23)   1.29 (1.10 to 1.52)
  \+ History of CVD                                                                                                  1.00 (Ref)                 0.84 (0.71 to 1.00)   1.07 (0.91 to 1.26)   1.34 (1.14 to 1.58)
  3 studies, 7040 participants 1185 cases                                                                                                                                                   
  Basic model[\*](#tf3-1){ref-type="table-fn"}                                                                       1.00 (Ref)                 0.84 (0.71 to 1.00)   1.06 (0.90 to 1.25)   1.32 (1.12 to 1.56)
  \+ Fasting glucose                                                                                                 1.00 (Ref)                 0.84 (0.71 to 1.00)   1.06 (0.90 to 1.24)   1.28 (1.09 to 1.50)
  3 studies, 7066 participants 1188 cases                                                                                                                                                   
  Basic model[\*](#tf3-1){ref-type="table-fn"}                                                                       1.00 (Ref)                 0.83 (0.70 to 0.99)   1.05 (0.89 to 1.23)   1.30 (1.10 to 1.53)
  \+ Anti‐hypertensive use                                                                                           1.00 (Ref)                 0.83 (0.70 to 0.98)   1.06 (0.90 to 1.24)   1.31 (1.11, 1.54)
  3 studies, 7055 participants, 1185 cases                                                                                                                                                  
  Basic model[\*](#tf3-1){ref-type="table-fn"}                                                                       1.00 (Ref)                 0.83 (0.70 to 0.99)   1.05 (0.89 to 1.23)   1.30 (1.10 to 1.53)
  \+ log triglycerides, total cholesterol, & HDL‐c                                                                   1.00 (Ref)                 0.82 (0.69 to 0.97)   1.04 (0.89 to 1.22)   1.28 (1.09 to 1.51)
  2 studies, 5364 participants 1038 cases                                                                                                                                                   
  Basic model[\*](#tf3-1){ref-type="table-fn"}                                                                       1.00 (Ref)                 0.82 (0.68 to 0.98)   1.06 (0.89 to 1.26)   1.26 (1.06 to 1.51)
  \+ Albumin                                                                                                         1.00 (Ref)                 0.82 (0.68 to 0.98)   1.08 (0.91 to 1.29)   1.30 (1.09 to 1.55)
  2 studies, 5345 participants 1036 cases                                                                                                                                                   
  Basic model[\*](#tf3-1){ref-type="table-fn"}                                                                       1.00 (Ref)                 0.81 (0.68 to 0.98)   1.05 (0.89 to 1.25)   1.26 (1.06 to 1.50)
  \+ log CRP                                                                                                         1.00 (Ref)                 0.80 (0.67 to 0.97)   1.01 (0.85 to 1.20)   1.15 (0.96 to 1.37)
  3 studies, 7073 participants 1189 cases                                                                                                                                                   
  Basic model                                                                                                        1.00 (Ref)                 0.83 (0.70 to 0.99)   1.12 (0.96 to 1.32)   1.30 (1.10 to 1.53)
  \+ Incident CHD as a time varying covariate                                                                        1.00 (Ref)                 0.82 (0.68 to 0.99)   1.13 (0.95 to 1.35)   1.38 (1.16 to 1.65)
  3 studies, 5528 participants 826 cases                                                                                                                                                    
  Excluding people with hx of CVD[\*](#tf3-1){ref-type="table-fn"}                                                   1.00 (Ref)                 0.78 (0.63 to 0.97)   1.12 (0.93 to 1.36)   1.33 (1.09 to 1.62)
  3 studies, 6188 participants 992 cases                                                                                                                                                    
  Excluding people using beta blockers[\*](#tf3-1){ref-type="table-fn"}                                              1.00 (Ref)                 0.79 (0.65 to 0.96)   1.04 (0.87 to 1.24)   1.31 (1.10 to 1.57)
  3 studies, 6838 participants 1085 cases                                                                                                                                                   
  Excluding first 2 years of follow‐up[\*](#tf3-1){ref-type="table-fn"}                                              1.00 (Ref)                 0.84 (0.70 to 1.00)   1.03 (0.87 to 1.22)   1.27 (1.07 to 1.50)

CVD indicates cardiovascular disease; HDL‐c, high‐density lipoprotein cholesterol.

Basic model incudes: age, sex, body mass index, history of diabetes, history of hypertension, smoking status, serum creatinine, and left ventricular hypertrophy.

![Hazard ratios for heart failure by heart rate using fractional polynomials model. Analyses involved data from 7073 participants (1181 incident heart failure events) with complete information on relevant factors. Hazard ratios were adjusted for age, sex, smoking status, history of diabetes, hypertension, body mass index, serum creatinine, fasting glucose, left ventricular hypertrophy, history of cardiovascular disease, use of anti‐hypertensive drugs and stratified by cohort. The HR (95% CI) using fractional polynomial models were plotted by solid and 95% CI by dashed lines.](jah3-4-e001364-g1){#fig01}

![Hazard ratio for heart failure by heart rate by participant‐level characteristics. Participants below resting heart rate (RHR) of 60 bpm were excluded. HR are calculated for a per‐10 bpm increase in RHR. *P* values for interaction were calculated from analyses using continuous variables where appropriate. Analyses were conducted using studies with information across all levels of each subgroup variable.](jah3-4-e001364-g2){#fig02}

Meta‐Analysis
-------------

Including the current 3 studies, we identified 7 population‐based prospective studies ([Figure 3](#fig03){ref-type="fig"}), reporting on the association between RHR and HF risk ([Table 4](#tbl04){ref-type="table"}). In a pooled analysis of 43 051 participants and 3476 HF events the combined RR for HF comparing the top versus the bottom fourth baseline RHR, typically adjusted for several conventional risk factors, was 1.40 (1.19 to 1.64) ([Figure 4](#fig04){ref-type="fig"}). There was moderate evidence of heterogeneity among the contributing studies (I^2^=54%, 95% CI: 0 to 80; *P*=0.04), which was not explained by any study‐level characteristics assessed. A significant proportion of the heterogeneity came from the MESA study, which observed the smallest number of events. There was no evidence of heterogeneity in pooled analysis excluding this study I^2^=0%, 95% CI: 0 to 75; *P*=0.78). Among the remaining studies, the pooled RR for HF was 1.31 (95% CI: 1.19 to 1.44), which was similar to the overall combined RR.

###### 

Prospective Studies Resting Heart Rate and Incident Heart Failure Contributing to Pooled Analyses

  Study          Location                         Population Source     Year of Baseline Survey   Age Range at Baseline (y)   Male (%)   Mean Follow‐Up (y)   No. of Cases   No. of Non‐Cases
  -------------- -------------------------------- --------------------- ------------------------- --------------------------- ---------- -------------------- -------------- ------------------
  CHS            USA                              Population register   1989--1990                65 to 100                   38.9       11.2                 857            3238
  Health ABC     USA                              Population register   1997--1998                68 to 80                    40.7       9.6                  177            1092
  KIHD           Finland                          Population register   1984--1989                42 to 61                    100        20.4                 151            1558
  MESA           USA                              Population register   2000--2002                45 to 84                    47.0       9.0                  112            4888
  PROSPER        Netherlands, Ireland, Scotland   Clinical trial        1997--1999                70 to 82                    49.0       3.2                  167            3917
  EPIC NORFOLK   UK                               Population register   1993--1997                39 to 79                    44.3       12.9                 1356           20 770
  ROTTERDAM      Netherlands                      Population register   1990--1993                ≥55                         38         14.6                 656            4112
  Total                                                                                                                                                       3476           39 575

ABC indicates Aging and Body Composition; CHS, Cardiovascular Health Study; KIHD, Kuopio Ischemic Heart Disease; MESA, Multi‐Ethnic Study of Atherosclerosis.

![Literature search strategy used for the meta‐analysis.](jah3-4-e001364-g3){#fig03}

![Relative risks for heart failure comparing top vs bottom fourth of heart rate. CHS indicates Cardiovascular Health Study; Health ABC, Heath Aging and Body Composition; KIHD, Kuopio Ischemic Heart Disease; MESA, Multi‐Ethnic Study of Atherosclerosis; RR, relative risk.](jah3-4-e001364-g4){#fig04}

Discussion
==========

In this population of middle‐aged to older individuals without HF at baseline, there were weak to modest associations of RHR with several conventional HF risk factors, and resting RHR was non‐linearly associated with risk of incident HF independent of other known risk factors. These findings remained consistent across several subgroups, including the presence or absence of pre‐existing cardiovascular disease or use of beta‐blockers, and were similar in analyses that adjusted for CHD events during follow‐up, excluded HF events recorded in the first 2 years of follow‐up, people with a history of CVD at baseline, or individuals who were using beta‐blockers. Pooled findings from the systematic meta‐analysis of 7 studies reinforces the validity and generalizability of these data suggesting that individuals in the top quartile of RHR had about a 30% higher risk of HF compared with individuals in the lower quartile of baseline RHR levels.

Elevated RHR has been previously recognized as a risk factor for HF in high‐risk individuals such as those with prevalent CHD and hypertension.^[@b3],[@b5],[@b23]^ Limited prospective evidence has been available for healthy middle‐aged adults. Whereas, a few prospective studies have shown a positive association of RHR with incident HF, these have failed to delineate in detail the nature and shape of this association. In contrast to prior evidence, we observed a non‐linear J‐shaped association of RHR with HF risk. An increased risk of HF was observed at both low and high levels of RHR, with risk rising progressively beyond a heart rate of 60 bpm. In line with the epidemiological evidence, findings from clinical trials of an RHR‐lowering agent have shown the benefit of lowering RHR.^[@b5],[@b23]^ In SHIFT (Systolic Heart failure treatment Trial)^[@b5]^ the role of a pure heart rate‐lowering agent, ivabradine was investigated in HF patients with RHR \>70 bpm despite beta‐blockade. It was observed that additional heart rate reduction was beneficial in reducing HF re‐hospitalizations and improves overall survival, providing further evidence that elevated RHR may be causally linked to HF risk and outcomes. However, evidence showing benefit of further lowering RHR to levels as low as 60 bpm while also taking into account the risks associated with lower heart rates needs to be further ascertained.

Several mechanistic pathways have been implicated in the causal link between elevated RHR and the development of HF. Among these, systemic inflammation and endothelial dysfunction have been commonly suggested.^[@b9]^ However, findings from the study by Nanchen and colleagues^[@b8]^ observed that these factors do not fully explain the risk of HF associated with elevated RHR. Higher resting heart rate may reflect decreased levels physical fitness and/or higher sympathetic tone relative to parasympathetic tone, which in turn are associated with HF.^[@b24]^ Although, it has been suggested that this association might be mediated by CHD, adjustment for either preceding CHD and incident CHD in our study did not attenuate the association between RHR and incident HF, which is similar to findings from previous studies.^[@b7]--[@b8]^ A chronic increase in RHR may lead to an increase in myocardial oxygen requirements and may contributes to ventricular remodeling and subsequently to regional and global left ventricular dysfunction,^[@b6]^ though this currently remains speculative.^[@b7]^ Further work is needed to help identify key underlying biological mechanisms through which RHR may play a role in the development of HF. Irrespective of whether RHR has a causal role in the etiology of HF, its potential utility for HF risk assessment warrants consideration, particularly as its measurement involves a simple, non‐invasive, and routine procedure in clinical practice.

These analyses have several strengths and limitations that merit consideration. Participants in the Health ABC, CHS, and KIHD studies were identified from general populations, are well characterized, involved high response and follow‐up rates, and have been prospectively monitored using established databases for hospital admissions and causes of death. Individuals with manifest HF or major rhythm disorders (ventricular conduction defect, major Q‐wave abnormality, isolated ST‐T wave abnormalities, atrial fibrillation, or atrio‐ventricular blocks) at baseline were excluded from the analyses, reducing the effects of any pre‐existing disease on RHR. As findings from these studies were reinforced by a meta‐analysis of 4 other long‐term population‐based prospective studies in Western countries, it increases the likelihood that these results can be generalized, to Western populations in general. Further studies are, however, needed in ethnic sub populations of Western countries and populations in non‐Western countries. Repeat measurements of RHR were not available, preventing the quantification of the extent of within‐person variability in RHR measurements. Also, individual patient‐level data was only available for 3 of the 7 cohorts, further limiting the participant‐level analysis that could be shown across all cohorts.

In conclusion, in Western populations there is a non‐linear association between resting heart rate and risk of incident HF, which is independent of conventional HF risk factors. Further assessment of the possible role of RHR reduction in HF prevention is warranted.
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